Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab in Lung Injury
NCT04848272Phase 1Active, not recruiting
- Sponsor
- St Vincent's Institute of Medical Research
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of lanadelumab in not applicable; "lung injury" is not a specific disease (4 arms), sponsored by St Vincent's Institute of Medical Research. Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 28 days. Started Aug 2021; status: active, not recruiting.
02
Drugs
lanadelumab
03
Conditions
not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on NCT04848272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848272.